Drugs / CSR02-Fab-TF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04601428 | Jan 2021 → Dec 2025 overdue | hepatocellular carcinoma | Koo Foundation Sun Yat-Sen Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSR02-Fab-TF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601428 ↗ |
| Action | Inhibit | “a new agent designed in the laboratory to block only tumor blood vessels” NCT04601428 ↗ |
| Modality | Protein / enzyme biologic | “a manufactured (recombinant) protein called CSR02-Fab-TF” NCT04601428 ↗ |
| Route | Other | “Intra-Arterial Infusion of CSR02-Fab-TF” NCT04601428 ↗ |
| Target | PLVAP | “An antibody, CSR02, was made that recognizes PLVAP and then the Fab portion of that antibody was combined with tissue factor” NCT04601428 ↗ |